Due to the rapid pace of research in hematologic malignancies, community hematology/oncology physicians often face difficulty synthesizing emerging and evolving data into routine patient care. The purpose of this 1-day symposium is to provide participants with expert insights from leading investigators in treatment selection and supportive care best practices for patients with acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, follicular lymphoma, mantle cell lymphoma, myelodysplastic syndromes, multiple myeloma, and T-cell lymphoma.

Upon completion of this activity, participants should be able to:

• Assess predictive and prognostic markers that affect treatment selection for patients with hematologic malignancies
• Differentiate current and emerging efficacy and safety data on novel therapies for hematologic malignancies
• Evaluate supportive care plans for patients with hematologic malignancies
• Apply recent advances to meet the needs of individual patients with hematologic malignancies

Learning objectives apply to all professions in the target audience.

Oncologists, hematologists, nurses, and other health care professionals involved in the treatment of patients with hematologic malignancies.

Click here to view the schedule.

Register by March 1, 2016 to receive 25% off.  For more information about fees, click here.

Please click here to register or give us a call at 855-276-6855.

Jointly Provided By

PHYSICIANS

USF Health designates this live activity for a maximum of 8.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSES
USF Health is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

A maximum of 8.5 contact hours may be earned by learners who successfully complete this continuing nursing education activity.